 SALT LAKE CITY, Nov. 16, 2020 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China. 